Format

Send to

Choose Destination
See comment in PubMed Commons below
Eur J Cancer. 2008 Nov;44(17):2615-22. doi: 10.1016/j.ejca.2008.08.010. Epub 2008 Sep 18.

The CAP-CR study: direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine.

Author information

1
PBE Consulting, Verona, Italy. stefania.lopatriello@pbe.it

Erratum in

  • Eur J Cancer. 2009 Aug;45(12):2228.

Abstract

AIM:

To describe the healthcare resource consumption of metastatic colorectal cancer (MCRC) patients in the Italian healthcare setting.

METHODS:

A retrospective chart analysis estimating direct medical costs of first-line infusional 5-Fluorouracil (5-FU) or oral Capecitabine (CAP), associated or not with other chemotherapies, from the Italian Healthcare Service (IHCS) and Hospital (H) perspectives.

RESULTS:

202 subjects were analysed. CAP patients (N=66) were older, with a more compromised clinical status and received less chemotherapy agents in association than 5-FU patients (N=136). From the IHCS perspective, mean total costs per patient were 12,029 euro and 5,781 euro in the 5-FU and CAP arms respectively; 7,338 euro and 4,688 euro from the H perspective. The infusional administration route of 5-FU was a cost driver from both perspectives. Sensitivity analyses found the results to be robust to variations in base case parameters.

CONCLUSIONS:

Management of MCRC by oral chemotherapies may be an economically advantageous option to both IHCS and hospitals.

PMID:
18805000
DOI:
10.1016/j.ejca.2008.08.010
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center